Zynerba Pharmaceuticals Inc ZYNE have dropped by about 12 percent since the company reported third-quarter results Nov. 8.
Analysts at HC Wainwright and Canaccord Genuity consider the sell-off an overreaction and issued positive updates on the company this week.
The Analysts
HC Wainwright's Oren Livnat reiterated a Buy rating on Zynerba with a $23 price target.
Canaccord Genuity's Arlinda Lee maintained a Buy rating with a $15 price target.
The Thesis
Zynerba's ZYN002 is a CBD-based drug for children and adolescents with Fragile X syndrome, a genetic condition that causes intellectual disability, behavioral and learning challenges and is thought to be a single-gene cause of autism spectrum disorder.
In its last earnings report, Zynerba reiterated all "expected pipeline timelines," said HC Wainwright's Livnat.
The company is showing financial discipline and is well-capitalized to survive through 2019, the analyst said.
The sell-side firm's model focuses solely on the ZYN002 candidate, and Livnat estimates an enterprise value of $34 million.
HC Wainwright's price target of $23 per share, which implies an upside of around 300 percent, includes a probability of success for ZYN002 of 35 percent of achieving $700 million in peak U.S. sales with an orphan indication, the analyst said.
Canaccord's Lee said Zynerba's earnings report reflects a lower-than-expected rate of cash burn. Zynerba has enough cash to last through through the important data for ZYN002's ongoing Phase 3 trials next year, the analyst said.
The Price Action
Zynerba Pharmaceuticals shares were down 3.36 percent at $5.47 at the time of publication Tuesday.
Related Links:
Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
The Benzinga Cannabis Capital Conference is coming to Florida
The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.
Get your tickets now on bzcannabis.com – Prices will increase very soon!